1.45p
+5.07%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Proteome Sciences
Its shares trade on LSE under the ticker PRM.L. It has been listed since 3 October 1995. In the fiscal year to 31 December 2025, it reported revenue of £3.8m and a net loss of £3.1m. At that date it held total assets of £8.3m and shareholders' equity of −£9.5m.
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications. The firm is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. The company operates through the EU (the United Kingdom and Germany) and the United States geographic regions. Through the United Kingdom segment, it provides protein separation and MS capabilities for identification and analysis of post-translational modification of proteins in protein phosphorylation, image analysis and bioinformatics. Through the Germany segment, it provides protein profiling technologies, such as Tandem Mass Tags (TMT), which offers quantitation of proteins for the discovery of biomarkers. The company has research agreements with various institutions in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 3 Oct 1995
- Employees
- 25
- Website
- proteomics.com ↗
Leadership
Pay as last reported
- Mr. Christopher PearceExecutive Chairman of the Board, since 2025£61,000
- Mr. Stefan FuhrmannFinance Director
- Dr. Ian PikeChief Scientific Officer, Executive Director, since 2010£249,000
- Mr. Richard DennisChief Commercial Officer, Executive Director, since 2018£197,000
- Mr. Martin DiggleNon-Executive Independent Director
- Mr. Roger McdowellNon-Executive Independent Director£35,000
- Dr. Ursula NeyNon-Executive Independent Director£33,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Leading Proteomics Technology:
- Proteome Sciences PLC possesses cutting-edge proteomics technology, allowing the company to identify, measure, and analyze proteins with high precision. This technology provides a strong competitive advantage in the field.
- Robust Intellectual Property Portfolio:
- The company holds a comprehensive intellectual property portfolio, including patents and trade secrets, protecting its innovative proteomics technology. This portfolio acts as a barrier to entry for potential competitors.
- Strategic Partnerships:
- Proteome Sciences has established strategic collaborations with renowned research institutions and pharmaceutical companies. These partnerships enable knowledge sharing, access to resources, and increase the company's market reach.
Weaknesses
- Reliance on Key Customers:
- A significant portion of Proteome Sciences' revenue comes from a few key customers. Dependency on a limited customer base exposes the company to the risk of customer-specific issues or loss of business if these relationships were to weaken.
- Limited Financial Resources:
- The company has limited financial resources, which may restrict its ability to invest in research and development, scale operations, or seize potential growth opportunities in a dynamic market environment.
Opportunities
- Growing Demand for Personalized Medicine:
- The increasing adoption of personalized medicine creates opportunities for Proteome Sciences' proteomics technology. By identifying specific protein biomarkers, the company can contribute to the development of targeted therapies and diagnostics.
- Expansion into New Markets:
- Proteome Sciences can explore expansion opportunities in emerging markets, such as Asia-Pacific and Latin America. These regions offer substantial growth potential due to their rising investments in healthcare and research infrastructure.
Threats
- Intense Competition:
- The proteomics industry is highly competitive, with both established companies and new entrants vying for market share. Proteome Sciences faces the risk of competitors developing comparable or superior proteomics technologies.
- Regulatory Challenges:
- Compliance with evolving regulatory frameworks governing proteomics research and commercialization can pose challenges for Proteome Sciences. Changes in regulations may require additional investments or impact the company's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.